Last reviewed · How we verify
Clinical Validation of Immunovia Next-Generation Blood Biomarker Test to Detect Early-Stage Pancreatic Cancer (CLARITI)
This is a case-control study to clinically validate the performance of a protein biomarker test to differentiate Stage I and Stage II pancreatic ductal adenocarcinoma (PDAC) patient samples from samples acquired from control patients not diagnosed with PDAC but at increased risk of disease due to familial/genetic history or clinical symptoms.
Details
| Lead sponsor | Immunovia, Inc. |
|---|---|
| Status | COMPLETED |
| Enrolment | 1066 |
| Start date | Mon Sep 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Mon Jan 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Pancreatic Cancer Stage I
- Pancreatic Cancer Stage II
- Cancer Diagnosis
- PDAC - Pancreatic Ductal Adenocarcinoma
Countries
Italy, Canada, United States, Norway